Advertisement

The Role of Hematopoietic Growth Factors in Nuclear and Radiation Accidents

  • R. P. Gale
  • A. Butturini
Conference paper
Part of the Experimental Hematology Today—1988 book series (HEMATOLOGY, volume 1988)

Abstract

Exposure to total body radiation results in dose dependent suppression of hematopoiesis (reviewed in 1–3). Variables influencing the extent of bone marrow suppression include total dose, dose rate, schedule, shielding, dose uniformity, as well as source-term parameters. Single-dose total body radiation at doses ≥ 1 Gy and dose rates ≥ 1 cGy per minute produce granulocytopenia and thrombocytopenia. Doses > 2 Gy can cause death from infection and bleeding. The 50% lethal dose (LD50) in humans is presumed to be 4–5 Gy based on data in animals. Higher radiation doses carry an increasing risk of death from bone marrow suppression; survival is unlikely after doses > 8–10 Gy. Doses > 15–20 Gy results in death from toxicity to other tissues such as the gastrointestinal tract or central nervous system.

Keywords

Hematopoietic Stem Cell Total Body Radiation Bone Marrow Suppression Bone Marrow Failure Nuclear Accident 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    UNSCEAR 1982. Ionizing radiation: sources and biologic effects. Report to the General Assembly, Vienna and New York.Google Scholar
  2. 2.
    Medical Research Council Committee on Effects of Ionizing Radiation. A forum on lethality from acute and protracted radiation exposure in man. Intl J Radiat Biol 1984; 46: 209–17.CrossRefGoogle Scholar
  3. 3.
    Mettler FA Jr, Moseley RD Jr: Medical Effects of Ionizing Radiation. New York Grune and Stratton. 1985.Google Scholar
  4. 4.
    Gale RP. Immediate medical consequences of nuclear accidents: Lessons from Chernobyl. JAMA 1987; 258: 625–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Gale RP. The role of bone marrow transplantation following nuclear accidents. Bone Marrow Transplantation 1987; 2: 1–6.PubMedGoogle Scholar
  6. 6.
    Gale RP. The medical response to radiation and nuclear accidents: Lessons for the future. J Natl Cancer Inst SubmittedGoogle Scholar
  7. 7.
    Gale RP, Reisner Y. Are bone marrow transplants effective after nuclear accidents? Lancet 1988; i:923–5.CrossRefGoogle Scholar
  8. 8.
    Abramson S, Miller RG, Phillips RA. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med 1977; 145: 1567–79.PubMedCrossRefGoogle Scholar
  9. 9.
    Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 1986; 45: 917–27.PubMedCrossRefGoogle Scholar
  10. 10.
    Roberts L. Radiation accident grips Goiania. Science. 1987; 238: 1028–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Golde DW, Takaku F (eds). Hematopoietic Stem Cells. New York, Marcel Dekker, Inc. 1985.Google Scholar
  12. 12.
    Wright DG, Greenberger JS (eds). Long-Term Bone Marrow Culture. New York, Alan R. Liss, Inc. 1984.Google Scholar
  13. 13.
    Metealf D. The molecular biology and functions of the granulocyte-marcophage colony-stimulating factors. Blood 1986; 67: 257–67.Google Scholar
  14. 14.
    Sieff CA. Hematopoietic growth factors. J Clin Invest 1987; 79: 1549–57.PubMedCrossRefGoogle Scholar
  15. 15.
    Clark SC, Kamen R. The human hematopoietic colony stimulating factors. Science 1987; 236: 1229–37.PubMedCrossRefGoogle Scholar
  16. 16.
    Donahue RE, Wange EA, Stone DK, et al. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 1986; 321: 872–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Welte K, Platzer E, Lu L, et al. Purification and biological characterization of human pluripotent hematopoietic colony stimulating factor. Proc Natl Acad Sci 1985; 82: 1526–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Donahue RE, Seehra J, Norton C, et al. Hematologic effects of recombinant human interleukin-3 (rhIL-3) and granulocyte/ macrophage colony-stimulating factor (rhGM-CSF) in primates. Proceedings of ASCO, Vol 7, March 1988, p 162.Google Scholar
  19. 19.
    Groopman JE, Mitsuyasu RT, DeLeo JM, Oette DH, Golde DW. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 593–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte- macrophate colony-stimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 870–6.CrossRefGoogle Scholar
  21. 21.
    Antman K, Griffin J, Elias A, et al. Use of rGM-CSF to ameliorate chemotherapy induced myelosuppression in sarcoma patients. Blood 1987; 70:Suppl 1: 129a.Google Scholar
  22. 22.
    Antin JH, Smith BR, Rosenthal DS, et al. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Blood 1987; 70:Suppl 1: 129a.Google Scholar
  23. 23.
    Morstyn G, Souza LM, Keech J, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; i:667–71.CrossRefGoogle Scholar
  24. 24.
    Butturini AB, De Souza PC, Gale RP, et al. Use of recombinant GM-CSF in the Brazil radiation accident. SubmittedGoogle Scholar
  25. 25.
    Blazar BR, Widmer MB, Soderling, et al. Augmentation of donor bone marrow engraftment in histoincompatible murine recipients by granulocyte-macrophage colony-stimulating factor. Blood 1988; 71: 320–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • R. P. Gale
  • A. Butturini

There are no affiliations available

Personalised recommendations